Finanzen von Neuphoria Therapeutics Inc (NEUP)NEUPNeuphoria Therapeutics Inc

Evaluating the bottom line, Neuphoria Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15.66%, while the net margin is -417.70%. These profitability ratios, combined with a Return on Equity (ROE) of -61.70%, provide a clear picture of how effectively NEUP converts its operational activities into shareholder value.

In the context of the broader market, NEUP competes directly with industry leaders such as AEON and CANF. With a market capitalization of $15.04M, it holds a leading position in the sector. When comparing efficiency, NEUP's gross margin of 100.00% stands against AEON's N/A and CANF's 100.00%. Such benchmarking helps identify whether Neuphoria Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Neuphoria's financials show volatility, with total revenues peaking at 15 million USD in Q3 2025 but dropping to 0 in subsequent quarters. The company reported a net income of -5,050,63 USD in Q3 2026, highlighting ongoing losses.